A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE)
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs MSDC 0602 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms EMMINENCE
- Sponsors Cirius Therapeutics
- 13 Oct 2017 Planned number of patients changed from 200 to 380.
- 13 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 Jul 2019.
- 13 Oct 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2019.